Lv1
100 积分 2024-07-24 加入
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
1天前
已完结
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
1天前
已完结
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
13天前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
18天前
已完结
Drug resistance in breast cancer: Mechanisms and strategies for management
1个月前
已完结
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial
1个月前
已完结
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
3个月前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
3个月前
已完结
Isolated Cubital Node Metastasis in a Treated Case of Breast Carcinoma on 18 F-FDG PET/CT: A Rare Finding
5个月前
已关闭
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
6个月前
已完结
皖公网安备34019202002308
